Menu Close

Global Retirement Partners LLC Buys 1,271 Shares of Zoetis Inc. (NYSE:ZTS)

Global Retirement Partners LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 11,539 shares of the company’s stock after purchasing an additional 1,271 shares during the period. Global Retirement Partners LLC’s holdings in Zoetis were worth $1,910,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sound View Wealth Advisors Group LLC lifted its holdings in Zoetis by 1.5% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 4,043 shares of the company’s stock worth $669,000 after buying an additional 60 shares in the last quarter. Seeyond raised its stake in Zoetis by 0.9% in the 3rd quarter. Seeyond now owns 6,965 shares of the company’s stock worth $1,152,000 after acquiring an additional 65 shares during the last quarter. Tarbox Family Office Inc. raised its stake in Zoetis by 29.4% in the 3rd quarter. Tarbox Family Office Inc. now owns 295 shares of the company’s stock worth $49,000 after acquiring an additional 67 shares during the last quarter. Equitable Holdings Inc. lifted its position in Zoetis by 2.3% during the 3rd quarter. Equitable Holdings Inc. now owns 2,977 shares of the company’s stock worth $492,000 after acquiring an additional 67 shares during the period. Finally, Harfst & Associates Inc. lifted its position in Zoetis by 3.2% during the 3rd quarter. Harfst & Associates Inc. now owns 2,190 shares of the company’s stock worth $362,000 after acquiring an additional 68 shares during the period. 92.50% of the stock is owned by institutional investors and hedge funds.

ZTS traded down $3.19 during trading hours on Wednesday, reaching $162.93. The company’s stock had a trading volume of 77,975 shares, compared to its average volume of 1,557,931. Zoetis Inc. has a fifty-two week low of $90.14 and a fifty-two week high of $176.64. The stock has a market cap of $77.44 billion, a PE ratio of 48.35, a P/E/G ratio of 4.35 and a beta of 0.71. The business’s 50-day moving average is $162.17 and its 200-day moving average is $158.00. The company has a debt-to-equity ratio of 2.41, a current ratio of 3.47 and a quick ratio of 2.60.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.19. The business had revenue of $1.79 billion for the quarter, compared to analysts’ expectations of $1.63 billion. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period last year, the firm earned $0.94 earnings per share. Analysts expect that Zoetis Inc. will post 3.63 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, March 1st. Shareholders of record on Wednesday, January 20th will be paid a $0.25 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a yield of 0.61%. The ex-dividend date is Tuesday, January 19th. Zoetis’s dividend payout ratio is currently 21.98%.

In other Zoetis news, EVP Heidi C. Chen sold 1,179 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $161.43, for a total value of $190,325.97. Following the transaction, the executive vice president now directly owns 17,514 shares in the company, valued at $2,827,285.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kristin C. Peck sold 10,500 shares of the stock in a transaction that occurred on Wednesday, November 25th. The shares were sold at an average price of $161.51, for a total transaction of $1,695,855.00. Following the completion of the transaction, the chief executive officer now owns 38,374 shares in the company, valued at $6,197,784.74. The disclosure for this sale can be found here. Insiders sold 110,606 shares of company stock worth $18,241,735 over the last quarter. 0.17% of the stock is currently owned by insiders.

A number of analysts have commented on the company. Morgan Stanley lifted their price target on Zoetis from $167.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, November 13th. BidaskClub raised Zoetis from a “hold” rating to a “buy” rating in a research report on Thursday, December 31st. Truist lifted their price target on Zoetis from $160.00 to $170.00 in a research report on Thursday, November 12th. Atlantic Securities assumed coverage on Zoetis in a research report on Monday, September 21st. They set an “overweight” rating and a $191.00 price target for the company. Finally, Barclays lifted their price target on Zoetis from $175.00 to $189.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $161.14.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: How do analysts define an oversold condition?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).



Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.